Key Takeaway: Forte Biosciences, Inc. has announced the issuance of equity inducement awards to new non-executive employees as part of its compliance with Nasdaq Listing Rules. The grants consist of options to purchase 25,000 shares of common stock, which will vest over four years. This initiative aims to attract talent to support the company's development of its anti-CD122 monoclonal antibody candidate, FB102.
Price reaction · baseline $26.44 (2026-03-17 close) · hit pre-market · clean, no other FBRX news in the window
day 0 close
-6%
day 1 · peak
-6.9%
day 3
-3.1%
Market Sentiment Analysis
POSITIVE FACTORS
Forte Biosciences is expanding its team with new hires.
Equity inducement awards may attract skilled professionals.
The company is focused on developing a promising therapeutic candidate.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+391%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
FB-401
Phase 2 · Atopic Dermatitis
Full Press Release Details
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 25,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company. The option awards shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee’s employment commencement date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to each individual’s continuous employment through each vesting date.
The inducement awards were made under Forte’s 2020 Inducement Equity Incentive Plan and related award agreements.
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Source: Forte Biosciences, Inc.
Frequently Asked Questions
What are the inducement grants by Forte Biosciences?
Forte Biosciences issued equity inducement awards to new non-executive employees as part of Nasdaq compliance.
How many shares were granted in the inducement awards?
The inducement awards consist of options to purchase a total of 25,000 shares of common stock.
What is the vesting schedule for the stock options?
The options will vest over four years, with 25% vesting after one year and the rest monthly.
What is the purpose of these inducement awards?
The awards aim to attract skilled professionals to support the company's development efforts.